StockData
Evolus, Inc. logo

Evolus, Inc. (EOLS) stock

EOLSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$6.69+0.06 (+0.90%)

Close on Nov 17, 2026Market cap $441.88MP/E –Yield –

Evolus price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Evolus's price to sales ratio was 1.5× on Nov 11, 2026, against 1.6× a year earlier. Over the last 5 years it ranged from 0.9× to 6.3×, with a median of 3.3×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20261.5×+0.0
2025Dec 31, 20251.5×−1.3
2024Dec 31, 20242.8×−0.4
2023Dec 29, 20233.3×+0.2
2022Dec 30, 20223.0×−1.2
2021Dec 31, 20214.2×+2.2
2020Dec 31, 20202.0×−19.5
2019Dec 31, 201921.6×–

More Evolus figures

See a number that looks wrong?